A Randomized, Double-blind, Placebo-controlled Study of Effects of Two Fixed-dose Leucine-sildenafil Combinations (NS-0300) or Two Fixed-dose Leucine-sildenafil-metformin Combinations (NS-0200) Versus Placebo on Body Weight in Obesity

This is a 24-week study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo. The primary objective of this study is to evaluate the percentage change in body weight in subjects from Baseline/Visit 2 (Day 1) to Study Termination/Visit 8 (Day 168/Week 24).

Start Date08 Jan 2018

Sponsor / Collaborator

NuSirt Biopharma, Inc.

NCT02546609

/ CompletedPhase 2

A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients

The goal of this study is to determine if NS-0200 can reduce the amount of liver fat in patients diagnosed with non-alcoholic fatty liver disease (NAFLD). This study will compare two doses of NS-0200 to placebo in NAFLD patients.

Start Date19 Nov 2015

Sponsor / Collaborator

NuSirt Biopharma, Inc.

100 Clinical Results associated with Sildenafil/Metformin/Leucine

100 Translational Medicine associated with Sildenafil/Metformin/Leucine

100 Patents (Medical) associated with Sildenafil/Metformin/Leucine

Literatures (Medical) associated with Sildenafil/Metformin/Leucine

01 Jan 2019·Obesity

Randomized Controlled Trial of a Leucine‐Metformin‐Sildenafil Combination (NS‐0200) on Weight and Metabolic Parameters

Article

Author: Rinella, Mary ; Barritt, A. Sidney ; Chalasani, Naga ; Flores, Omar ; Kolterman, Orville ; Vuppalanchi, Raj ; Zemel, Michael B. ; Siddiqui, Mohammad

ObjectiveLeucine was previously demonstrated to allosterically activate mammalian sirtuin 1 and synergize with other sirtuin 1/AMP‐activated protein kinase/nitric oxide pathway activators to modulate energy metabolism. The objective of this study was to evaluate the effects of a triple combination of leucine, metformin, and sildenafil (NS‐0200) on body weight and obesity comorbidities in a phase 2 randomized trial.MethodsA total of 91 subjects with obesity were randomized to placebo, low dose (1.1 g leucine/0.5 g metformin/0.5 mg sildenafil), or high dose (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil) twice daily for 16 weeks. Seventy subjects completed the trial and met all a priori compliance criteria. Hypertensive (n = 35) and hypertriglyceridemic (n = 22) subcohorts were also analyzed.ResultsNS‐0200 dose‐responsively reduced weight; high dose reduced weight by 2.4 and 5.0 kg in the full and high‐triglyceride cohorts, respectively (P < 0.0001). High‐dose NS‐0200 treatment also decreased blood pressure (−5.5 mm Hg diastolic pressure; P = 0.011), with greater effects among hypertensive subjects. NS‐0200 also significantly reduced triglycerides and hemoglobin A1c. Significant improvement in ≥ 2 comorbidities was exhibited by 54% of subjects in the high‐dose arm versus 5% of placebo subjects (P = 0.0009). Treatment‐emergent adverse events did not significantly differ among groups.ConclusionsThese data support further study of NS‐0200 as a therapy for obesity and associated comorbidities.

100 Deals associated with Sildenafil/Metformin/Leucine

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 2	-	Nusirt Sciences, Inc.	-
Obesity	Preclinical	United States	NuSirt Biopharma, Inc.	08 Jan 2018
Metabolic dysfunction-associated steatotic liver disease	Preclinical	United States	NuSirt Biopharma, Inc.	19 Nov 2015
Nonalcoholic Steatohepatitis	Preclinical	United States	Nusirt Sciences, Inc.	19 Nov 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02546609 (Pubmed)	Phase 2	Metabolic dysfunction-associated steatotic liver disease	91	Placebo	ecvmubzwna(ptkgrbkljf) = tezrolqpgg vcvmmxckmw (seyteqslun )	-	01 Jan 2019
				High dose (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil)	(plcmefjprl) = sitykisyed oxtoqhkhru (eokofmlqim ) View more
NCT03364335 (CTgov)	Phase 2	Obesity	267	Placebo (Placebo)	qihmoaeogq(xobtltipad) = geguerjwqo gdrqrmmwhq (rtamggoxun, lisysoexfe - gzwgmzoroy) View more	-	27 Nov 2018
				Leu Sil 4.0mg (Leu Sil 1.0mg)	qihmoaeogq(xobtltipad) = xcluyzlmhs gdrqrmmwhq (rtamggoxun, nzgeafzczw - cupserywkz) View more
NCT02546609 (CTgov)	Phase 2	Metabolic dysfunction-associated steatotic liver disease	91	Placebo (Placebo)	otlqhuftzy(gemgilcyut) = sgittdgnzz oojosizoyx (rfnunpwxcs, scegxicfzz - pqipmnsqwa) View more	-	02 May 2018
				Leu-Met-Sil 1.0 (Leu Met Sil 0.5mg)	otlqhuftzy(gemgilcyut) = nbaczemrab oojosizoyx (rfnunpwxcs, yyukqaozbs - xrocurvzzg) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sildenafil/Metformin/Leucine

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation